Trevor Millar - NeonMind Biosciences Advisor
| NMDBFDelisted Stock | USD 0.50 0.00 0.00% |
Insider
Trevor Millar is Advisor of NeonMind Biosciences
| Phone | 866 811 8960 |
| Web | https://www.neonmindbiosciences.com |
NeonMind Biosciences Management Efficiency
The company has return on total asset (ROA) of (1.8822) % which means that it has lost $1.8822 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (37.2157) %, meaning that it generated substantial loss on money invested by shareholders. NeonMind Biosciences' management efficiency ratios could be used to measure how well NeonMind Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.NeonMind Biosciences has accumulated 450.01 K in total debt with debt to equity ratio (D/E) of 1.58, which is about average as compared to similar companies. NeonMind Biosciences has a current ratio of 0.58, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist NeonMind Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, NeonMind Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like NeonMind Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for NeonMind to invest in growth at high rates of return. When we think about NeonMind Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | INSIDER Age | ||
| Keith MD | X4 Pharmaceuticals | 53 | |
| Marine Popoff | Hookipa Pharma | N/A | |
| John Kanakis | Cybin Inc | 43 | |
| Florian Brand | ATAI Life Sciences | 37 | |
| Alex Nivorozhkin | Cybin Inc | 64 | |
| Aaron Bartlone | Cybin Inc | 57 | |
| Lukas Flatz | Hookipa Pharma | N/A | |
| Madison Crawford | ATAI Life Sciences | N/A | |
| Senthil Sundaram | Terns Pharmaceuticals | 46 | |
| Prof MD | Hookipa Pharma | 80 | |
| Thomas Schaible | Fortress Biotech | N/A | |
| LLB LLB | Cybin Inc | 48 | |
| Reinhard Kandera | Hookipa Pharma | 55 | |
| Richard MD | X4 Pharmaceuticals | 61 | |
| Schond Greenway | Mind Medicine | 52 | |
| Weidong Zhong | Terns Pharmaceuticals | 58 | |
| Leonard Latchman | Mind Medicine | N/A | |
| Mark Vignola | Terns Pharmaceuticals | 46 | |
| Mike Preigh | Day One Biopharmaceuticals | N/A | |
| Paul Glavine | Cybin Inc | 35 | |
| Andreas Bergthaler | Hookipa Pharma | N/A | |
Management Performance
| Return On Equity | -37.22 | |||
| Return On Asset | -1.88 |
NeonMind Biosciences Leadership Team
Elected by the shareholders, the NeonMind Biosciences' board of directors comprises two types of representatives: NeonMind Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NeonMind. The board's role is to monitor NeonMind Biosciences' management team and ensure that shareholders' interests are well served. NeonMind Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NeonMind Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| BA BA, CEO CoFounder | ||
| Tamara Melck, Chief Officer | ||
| Robert Tessarolo, Pres Chairman | ||
| Ernie Ho, VP Devel | ||
| CPA CGA, Chief Officer | ||
| Trevor Millar, Advisor |
NeonMind Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is NeonMind Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -37.22 | |||
| Return On Asset | -1.88 | |||
| Operating Margin | 735.17 % | |||
| Current Valuation | 799.08 K | |||
| Shares Outstanding | 35.82 M | |||
| Price To Book | 12.19 X | |||
| Price To Sales | 18.10 X | |||
| Gross Profit | (84.45 K) | |||
| EBITDA | (6.65 M) | |||
| Net Income | (7.21 M) |
Currently Active Assets on Macroaxis
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in NeonMind Pink Sheet
If you are still planning to invest in NeonMind Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the NeonMind Biosciences' history and understand the potential risks before investing.
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories |